Leading cell and therapy Group, Oxford BioMedica plc, has announced it has agreed a two-year £2m collaboration project focused on gene and cell therapy manufacturing.
The gene therapy project aims to deliver tangible benefits to patients by shortening the time-to-clinic and time-to-market – image courtesy of OxfordBioMedica The collaboration’s aim is to explore and apply novel advanced technologies to further evolve OXB’s proprietary suspension LentiVector® platform to deliver even higher quality vectors for both clinical and…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
